Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6536
    +0.0013 (+0.20%)
     
  • OIL

    83.86
    +0.29 (+0.35%)
     
  • GOLD

    2,352.20
    +9.70 (+0.41%)
     
  • Bitcoin AUD

    98,110.62
    -615.95 (-0.62%)
     
  • CMC Crypto 200

    1,332.10
    -64.43 (-4.62%)
     
  • AUD/EUR

    0.6106
    +0.0033 (+0.55%)
     
  • AUD/NZD

    1.0992
    +0.0034 (+0.31%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,717.80
    +287.30 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,278.07
    +192.27 (+0.50%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Here's How Moderna Could Top $450 Again

Here's How Moderna Could Top $450 Again

Moderna (NASDAQ: MRNA) shares have dropped 70% since their record high of more than $450 last August. The second reason has to do with Moderna specifically. The company's only commercialized product right now is the coronavirus vaccine, so investors worry about earnings if vaccine demand drops in a post-pandemic world.